AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
18 Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
21 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States, Harvard Medical School, Boston, Massachusetts, United States
ABSTRACT
Introduction: Idecabtagene vicleucel (ide-cel), a BCMA-directed CAR-T cell therapy, has demonstrated deep, durable responses in patients (pts) with relapsed and refractory multiple myeloma (RRMM). Despite these promising results, patients invariably relapse post CAR-T cell therapy, due to lack of CAR-T cell persistence or T-cell exhaustion, changes in tumor microenvironment and target antigen loss. Elotuzumab, a monoclonal antibody targeting SLAMF7 on multiple myeloma (MM) cells, augments immune-mediated cytotoxicity through the direct activation of NK cells. Iberdomide is a cereblon modulator that induces enhanced degradation of Ikaros and Aiolos compared with immunomodulatory agents to exert direct anti-myeloma activity; iberdomide has been shown to enhance the proliferation, expansion, and functionality of manufactured CAR-T, while preventing exhaustion. We hypothesize that the combination of elotuzumab and iberdomide, though their synergistic mechanisms of action, will lead to greater persistence of CAR-T cells and suppress tumor growth with a favorable toxicity profile.
Methods: Adult pts with RRMM who received ≥ 2 prior lines of therapy (pLOT) and had a partial response or better 60-90 days after ide-cel were eligible. Pts received a single ide-cel infusion (150-450 × 106 CAR-positive T cells). The phase 1 dose expansion follows a standard “3+3” dose escalation design starting with 0.75 mg dose of iberdomide taken orally for days 1 to 21 of 28-day cycle with escalation to 1mg dose if no dose limiting toxicities (DLTs) observed. Elotuzumab is administered intravenously at a dose of 10mg/kg on days 1, 8, 15, and 22 for cycles 1 and 2 and then at a dose of 20mg/kg on day 1 of cycles 3 and beyond and dexamethasone 40mg administered orally or intravenously weekly for cycles 1 and 2 and then on days 1 of subsequent cycles, with treatment continued until progression. The primary endpoint was safety and tolerability of the combination and progression-free survival (PFS) at 12 months. Secondary endpoints include time-to-progression, overall survival (OS), and duration of response (DOR) with exploratory endpoints including minimal residual disease (MRD) status.
Results: At the time of data cutoff, 6 patients have been enrolled with a median follow-up of 6 months from the initiation of maintenance therapy (Range 3-12). No DLTs were observed in the dose escalation cohort, and patients are now enrolling into the expansion portion of trial at the maximum tolerated dose (MTD) of iberdomide 1mg. The median age is 76 (range 72-77) with 2 females (33%) and 4 males (66%). Median pLOT was 4 (range 3-7) and all patients (100%) were triple-class refractory. One third of patients with evaluable FISH results had high-risk abnormalities per 2025 IMS-IMWG Consensus Genomic Staging as follows: 1q gain (3 pts), t(14,16) (1 patient), and 17p deletion (1 patient).
The most common toxicities of any grade (Gr) were neutropenia (n=6/6; 100%), leukopenia (n=5/6; 83%), fatigue (n=5/6; 83%), hyperglycemia (n=5/6; 83%), diarrhea (n=4/6; 67%), and edema (n=4/6; 67%). The most common Gr ≥3 toxicities were neutropenia (n=1/6, 17%), leukopenia (n=1/6, 17%), anemia (n=1/6, 17%), and thrombocytopenia (n=1/6, 17%). Infections occurred in 5 patients and were low grade; they consisted of upper respiratory infections (2 pts), urinary tract infections (2 pts), and a salivary gland infection (1 patient). There were no Gr ≥ 3 infections or non-hematologic toxicities, and no pts with treatment discontinuation or dose-reductions at data cutoff.
All 6 pts (100%) have achieved a complete response, with deepening of response observed in one-third of patients while on maintenance therapy. Of those evaluable for MRD testing (n=5), 5 pts (100%) achieved and sustained (≥ 6 months) MRD negativity at 10-6 threshold via next generation sequencing. No patients have progressed on treatment, and median PFS and OS have not been reached.
Conclusions: This is the first study evaluating the role of maintenance therapy with elotuzumab and iberdomide after CAR T-cell therapy in an older patient cohort treated with ide-cel. This novel combination demonstrates a favorable safety profile with no DLTs in the dose escalation cohort, low incidence of grade 3 neutropenia, and no grade 3 infections. The combination is highly effective with 100% CR and sustained MRD-negative disease in all evaluable patients to date. Enrollment in the expansion cohort is ongoing.